Efficacy & tolerability of ondansetron compared to metoclopramide in dose dependent cisplatin-induced delayed emesis

Indian Journal of Medical Research

Volumn 120, Issue 3, 2004, Pages 183-193

  Bhatia, Ashima ^a,c   Tripathi, K D ^a   Sharma, Manoj ^b  

^a MAULANA AZAD MEDICAL COLLEGE   (India)

^b LN Hospital   (India)

^c NONE   (India)

Author keywords

Cisplatin; Delayed emesis; Dexamethasone; Metoclopramide; Ondansetron

Indexed keywords

BLEOMYCIN; CISPLATIN; DEXAMETHASONE; FLUOROURACIL; METOCLOPRAMIDE; ONDANSETRON;

ADULT; AKATHISIA; ARTICLE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXPOSURE; DRUG INDUCED DISEASE; DRUG INFUSION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TOLERABILITY; DYSTONIA; EPIGASTRIC PAIN; FEMALE; HEAD AND NECK CANCER; HEADACHE; HEARTBURN; HUMAN; HUMAN TISSUE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; MUSCLE WEAKNESS; NAUSEA; NERVOUSNESS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; UTERINE CERVIX CANCER;

ADULT; ANTIEMETICS; CISPLATIN; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HUMANS; METOCLOPRAMIDE; NEOPLASMS; ONDANSETRON; VOMITING;

EID: 6444227943     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM, et al. On the receiving end-patient perception of the side effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983; 19 : 203-8.
2. Cubeddu LX, Hoffmann IS, Fuenmayor NT, Finn AL. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med 1990; 322 : 810-6.
3. Kris MG, Gralla RJ, Clark RA, Tyson LB, O'Connell JP, Wertheim MS, et al. Incidence, course and severity of delayed nausea and vomiting following the administration of high dose cisplatin. J Clin Oncol 1985; 3 : 1379-84.
4. Gandara DR. Progress in the control of acute and delayed emesis induced by cisplatin. Eur J Cancer 1991; 27 (Suppl 1) : S9-11.
5. Kris MG, Gralla RJ, Tyson LB, Clark RA, Cirrincione C, Groshen S. Controlling delayed vomiting : double blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 1989; 7 : 108-14.
6. Roila F, Boschetti E, Tonato M, Basurto C, Bracarda S, Picciafuoco M, et al. Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study. Am J Clin Oncol 1991; 14 : 238-42.
7. Clark RA, Gralla RJ. Delayed emesis: A dilemma in antiemetic control. Support Care Cancer 1993; 1 : 182-5.
8. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian group for Antiemetic Research. J Clin Oncol 1997; 15 : 124-30.
9. Navari RM, Madajewicz S, Anderson N, Tchekmedyian NS, Whaley W, Garewal H, et al. Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo. J Clin Oncol 1995; 13 : 2408-16.
10. Johnston D, Latreille J, Laberge F. Preventing nausea and vomiting during days 2-7 following high dose cisplatin chemotherapy. A study by the National Cancer Institute of Canada Clinical Trials Group. Proc Am Soc Clin Oncol 1995; 14 : 529-33.
11. de Mulder PH, Seynaeve C, Vermorken JB, van Liessum PA, Mols-Jevdevic S, Allman EL, et al. Ondansetron compared with high dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind crossover study. Ann Intern Med 1990; 113 : 834-40.
12. Passalacqua R, Cocconi G, Bella M, Monici L, Michiara M, Bandini N, et al. Double-blind, randomized trial for the control of delayed emesis in patients receiving cisplatin: comparison of placebo vs. adrenocorticotropic hormone (ACTH). Ann Oncol 1992; 3 : 481-5.
13. Shinkai T, Saijo N, Eguchi K, Sasaki Y, Tamura T, Fijiwara Y, et al. Control of cisplatin-induced delayed emesis with metoclopramide and dexamethasone: a randomized controlled trial. Jpn J Clin Oncol 1989; 19 : 40-4.
14. Gandara DR, Harvey WH, Monaghan GG, Perez EA, Stokes C, Bryson JC, et al. The delayed emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo. Semin Oncol 1992; 19 (4, Suppl 10) : 67-71.
15. Bhatia A, Tripathi KD, Sharma M. Comparison of ondansetron with metoclopramide in prevention of acute emesis associated with low dose and high dose cisplatin chemotherapy. Indian J Med Res 2003; 118 : 33-41.
16. Roila F, Tonato M, Cognetti E, Cortesi F, Favalli G, Marangolo M, et al. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 1991; 9 : 675-8.
17. Rosell R, Abad-Esteve A, Ribas-Mundo M, Moreno I. Evaluation of a combination of antiemetic regimen including IV high-dose metoclopramide, dexamethasone, and diphenhydramine in cisplatin-based chemotherapy regimens. Cancer Treat Rep 1985; 69 : 909-10.
18. Smyth JF, Coleman RE, Nicolson M, Gallmeier WM, Leonard RC, Cornbleet MA, et al. Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron? Br Med J 1991; 303 : 1423-6.
19. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: Maclleod CM, editor. Evaluation of chemotherapeutic agents. New York: Columbia University Press; 1949 p. 191-205.
20. Olver LN. Methodology in antiemetic trials. Oncology 1992; 49 : 269-72.
21. Del Favero AD, Roila F, Basurto C, Minott V, Ballatori E, Patoia L, et al. Assessment of nausea. Eur J Clin Pharmacol 1990; 38 : 115-20.
22. Lee CW, Suh CW, Lee JS, Lee KH, Cho GY, Kim SW, et al. Ondansetron compared with ondansetron plus metoclopramide in the prevention of cisplatin induced emesis. J Korean Med Sci 1994; 9 : 369-75.
23. Kaasa S. Measurement of quality of life in clinical trials. Oncology 1992; 49 : 289-94.
24. Advani SH, Gopal R, Dhar AK, Lal HM, Cooverji ND. Comparative evaluation of the clinical efficacy and safety of ondansetron and metoclopramide in the prophylaxis of emesis induced by cancer chemotherapy regimens including cisplatin. J Assoc Physicians India 1996; 44 : 127-30.
25. Kris MG, Tyson LB, Clark RA, Gralla RJ. Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis. Cancer 1992; 70 (4 Suppl 1) : 1012-6.
26. Hesketh P. Management of cisplatin-induced delayed emesis. Oncology 1996; 53(Suppl I) : 73-7.
27. Lim AK, Haron MR, Yap TM. Ondansetron against metoclopramide/dexamethasone - a comparative study. Med J Malaysia 1994; 49 : 231-8.
28. Soukop M, McQuade B, Hunter E, Stewart A, Kaye S, Cassidy J, et al. Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. Oncology 1992; 49 : 295-304.
29. Kris MG, Gralla RJ, Tyson LB, Clark RA, Kelsen DP, Reilly LK, et al. Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients. Cancer 1985; 55 : 527-34.
30. Allan SG, Cornbleet MA, Warrington PS, Golland IM, Leonard RC, Smyth JN. Dexamethasone and high dose metoclopramide: efficacy in controlling cisplatin induced nausea and vomiting. BMJ 1984; 289 : 878-9.
31. Bruera ED, Roca E, Cedaro L, Chacon R, Estevez R. Improved control of chemotherapy-induced emesis by the addition of dexamethasone to metoclopramide in patients resistant to metoclopramide. Cancer Treat Rep 1983; 67 : 381-3.
32. Strum SB, McDermed JE, Liponi DF. High-dose intravenous metoclopramide versus combination high-dose metoclopramide and intravenous dexamethasone in preventing cisplatin-induced nausea and emesis: a single-blind crossover comparison of antiemetic efficacy. J Clin Oncol 1985; 3 : 245-51.
33. Blackwell CP, Harding SM. The clinical pharmacology of ondansetron. Eur J Cancer Clin Oncol 1989; 25 (Suppl 1 : S 21-4.